Menu Search
Equities

Biosynex SA

0DL:DUS

Biosynex SA

Actions
  • Price (EUR)3.97
  • Today's Change-0.075 / -1.85%
  • Shares traded-1.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of May 16 2024 07:12 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Biosynex SA is a France-based company that specializes in the research, development and manufacture of in-vitro diagnostic kits aimed at health professionals. The Company’s products are used by biological and analytical services laboratories, obstetric units and emergency units, as well as in medical resource-limited settings. Biosynex SA specializes in four fields: tropical diseases, emergency markers, infectious diseases and autoimmunity. The Company’s products include Amnioquick (Obstetrics); Immunoquick Malaria Falciparum and Immunoquick Malaria +4 (Parasitology); Immunoquick Elifa HSV IGG, Immunoquick Elifa EBV G and Immunoquick Mono (Virology); Immunoquick Filtration CELIAC IgA and Immunoquick TG (Autoimmunology); and Immunoquick Tetanus (Bacteriology). It operates through Fumouze Diagnostics and SR2B.

  • Revenue in EUR (TTM)93.05m
  • Net income in EUR-13.79m
  • Incorporated2005
  • Employees560.00
  • Location
    Biosynex SA22 Boulevard Sebastien BrantILLKIRCH-GRAFFENSTADEN 67400FranceFRA
  • Phone+33 388787887
  • Fax+33 388787678
  • Websitehttps://www.biosynex.com
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		ALBIO:PAR since
announced		Transaction
value
ProciseDx CorpDeal completed12 Jun 202312 Jun 2023Deal completed-54.52%--
Laboratoires Innoxa SAS-Eye ActivityDeal completed08 Jun 202308 Jun 2023Deal completed-56.30%--
Data delayed at least 15 minutes, as of May 16 2024.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.